On the fly News and insights, exclusive to thefly.com



$5.47 /

-6.715 (-55.11%)


JPMorgan downgrades Athenex on 'huge surprise' from FDA

JPMorgan analyst Ling Wang downgraded Athenex to Neutral from Overweight with a price target of $7, down from $30. The stock closed Monday down 55%, or $6.64, to $5.46. The Complete Response Letter from the FDA in relation to the Oraxol filing in metastatic breast Cancer is a "huge surprise," Wang tells investors in a research note. The analyst is "very puzzled and disappointed" with the outcome and awaits further clarity upon management's meeting with the FDA. The setback opens up downside risk in the shares "due to a lack of clear near-term key value driver," says Wang. The analyst is concerned that the stock move may not wait till there is "full visibility."

  • 01


  • 10


ATNX Athenex
$5.47 /

-6.715 (-55.11%)

03/01/21 SVB Leerink
Athenex downgraded to Market Perform from Outperform at SVB Leerink
03/01/21 JPMorgan
Athenex downgraded to Neutral from Overweight at JPMorgan
03/01/21 Laidlaw
Athenex price target lowered to $13 from $38 at Laidlaw
03/01/21 Needham
Athenex downgraded to Hold from Buy at Needham

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.